Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FX8A3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on September 25, 2025, by the Defense Logistics Agency for the supply of Xtandi 80 mg tablets (60-count packages) with a ceiling value of $4,169.59. This firm fixed-price delivery order, which has an ultimate completion date of September 26, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program. The SPE2DB IDC, valued at $500 million and valid through November 2026, enables the Defense Logistics Agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting medical supply needs of military health facilities worldwide. No set-aside designation was utilized for this award.
Xtandi is an oncology medication used in the treatment of advanced prostate cancer, reflecting DMS Pharmaceutical Group's established role as a key supplier of specialty pharmaceutical products to the federal healthcare system. The contractor has consistently secured contracts with the Defense Logistics Agency for branded and generic prescription drugs, biologics, and medical consumables without set-aside designations, leveraging its woman-owned small business status to compete effectively in federal procurement markets. The Park Ridge, Illinois location serves as both the place of performance and the company's headquarters, positioning it to efficiently deliver pharmaceutical products to Department of Defense healthcare sites nationwide.
Quick answers
Who was awarded contract SPE2DB25FX8A3?
SPE2DB25FX8A3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 25, 2025.
How much is contract SPE2DB25FX8A3 worth?
The government has obligated $4,170 on SPE2DB25FX8A3.
Is contract SPE2DB25FX8A3 an order under another contract?
Yes. SPE2DB25FX8A3 is a delivery order under SPE2DB20D9354, an indefinite delivery contract.
Was contract SPE2DB25FX8A3 competed?
The extent of competition for SPE2DB25FX8A3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award